Corticosteroid sparing effects of treatment with guselkumab in patients with moderately to severely active Crohn's disease: Phase 3 GRAVITI study results through week 48

A. Hart,¹ R. Panaccione,² F. Steinwurz,³ Q. Cao,⁴ T. Hisamatsu,⁵ S. Nancey,⁶ M. Olurinde,⁷ Z. Yang,⁷ E. Merrall,⁸ N.A. Terry,⁷ B.E. Sands⁹

¹London North-West University Healthcare NHS Trust, London, UK; ²University of Calgary, Calgary, AB, Canada; ³Hospital Israelita Albert Einstein, São Paulo, Brazil; ⁴Sir Run Run Shaw Hospital Affiliated with School of Medicine, Zhejiang University, Hangzhou, China; ⁵Kyorin University, Tokyo, Japan; ⁶Hospices Civils de Lyon, Hôpital Lyon Sud, Lyon, France; ⁷Johnson & Johnson, Spring House, PA, USA; ⁸Johnson & Johnson, Leiden, the Netherlands; ⁹Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, USA


Background

- Achieving and maintaining corticosteroid (CS)-free remission is a treatment goal for **FT** Crohn's disease (CD)
- Guselkumab is a dual-acting IL-23p19 subunit inhibitor that binds to IL-23 and CD64, a receptor on cells that produce IL-23

GRAVITI is a Phase 3 double-blind, placebo-controlled, treat-through study evaluating the efficacy and safety of subcutaneous (SC) induction and maintenance treatment with guselkumab in participants with CD

Objective

To evaluate the CS-sparing effects of treatment with guselkumab vs placebo through Week 48 in the GRAVITI study



Key Takeaways

Among all participants receiving oral corticosteroids at baseline, greater proportions of guselkumab-treated participants were corticosteroid-free at Week 48 or for ≥90 days prior to Week 48 vs placebo

P0872

In participants with moderately to severely active CD, greater proportions of guselkumab-treated participants achieved corticosteroidfree clinical and endoscopic outcomes at Week 48 vs placebo

Methods


- Participants were randomized 1:1:1 to:
- Guselkumab 400mg SC every 4 wks (q4w)→200mg SC q4w
- Guselkumab 400mg SC q4w→100mg SC q8w
- Placebo
- Placebo participants who met rescue criteria were eligible for rescue treatment with guselkumab at Week 16
- For participants receiving oral CS at baseline, doses were maintained through Week 12
- Mandatory oral CS tapering began at Week 12 unless medically not feasible
- Outcomes evaluated at Week 48:

Outcome	Definition
Clinical remission*	CDAI score <150
CS-free clinical remission	CDAI score <150 and not receiving CS
90-day CS-free clinical remission	CDAI score <150 and not receiving CS for ≥90 days prior to the visit
Endoscopic response*	≥50% improvement from baseline in the SES-CD score
Endoscopic remission	SES-CD score ≤4 and at least a 2-point reduction from baseline and no subscore >1 in any individual component
90-day CS-free endoscopic response	≥50% improvement from baseline in SES-CD score and not receiving corticosteroids for ≥90 days prior to the visit
90-day CS-free endoscopic remission	SES-CD score ≤4 and a ≥2-point reduction from baseline and no subscore >1 in any individual component and not receiving corticosteroids for ≥90 days prior to the visit

Figure 1. Phase 3, double-blind, treat-through design: GRAVITI

Key eligibility criteria

- Moderately to severely active CD (CDAI score 220–450 AND either mean daily SF count ≥4 OR AP score ≥2) and SES-CD score ≥6 (or ≥ 4 for isolated ileal disease)
- Inadequate response/intolerance to oral corticosteroids, 6-MP/AZA/MTX, or biologic therapies^a



^aBiologic therapies: TNF antagonists or vedolizumab. 6-MP=6-mercaptopurine; AP=abdominal pain; AZA=azathioprine; BIO=biologic; CDAI=Crohn's Disease Activity Index; MTX=methotrexate; SC=subcutaneous; SES-CD=Simple Endoscopic Score for Crohn's Disease; SF=stool frequency.

Results

Table 1. Baseline demographics and disease characteristics

*Multiplicity controlled. CDAI=Crohn's Disease Activity Index; CS=corticosteroid; SES-CD=Simple Endoscopic Score for Crohn's Disease.

• All 90-day CS-free analyses were not multiplicity controlled


		Gusell		
Full analysis set	Placebo SC (N=117)	400 mg SC q4w → 100 mg SC q8w (N=115)	400 mg SC q4w → 200 mg SC q4w (N=115)	7 Total (N=347)
Demographics				
Age in years, mean (SD)	36.0 (12.71)	37.4 (13.32)	39.1 (12.56)	37.5 (12.89)
Men, n (%)	67 (57.3%)	66 (57.4%)	70 (60.9%)	203 (58.5%)
Characteristics				
CD duration in years, mean (SD)	7.0 (7.75)	9.2 (9.08)	7.9 (7.13)	8.0 (8.05)
CDAI score, mean (SD)	293.0 (49.09)	300.4 (54.32)	297.3 (54.69)	296.9 (52.68)
SES-CD score, mean (SD)	12.0 (6.89)	12.2 (6.85)	11.8 (7.12)	12.0 (6.94)
Involved GI areas by central read	l er, n (%)			
Colon only	40 (34.2%)	41 (35.7%)	40 (34.8%)	121 (34.9%)
lleum only	22 (18.8%)	25 (21.7%)	27 (23.5%)	74 (21.3%)
lleum and Colon	55 (47.0%)	49 (42.6%)	48 (41.7%)	152 (43.8%)
Biomarkers				- C
CRP in mg/L, median (IQR)	7.9 (2.1; 14.7)	5.2 (1.7; 13.3)	5.7 (1.7; 16.1)	5.8 (1.8; 14.9)
Fecal calprotectin in µg/g, ª median (IQR)	712.0 (243.0; 1724.0)	610.0 (226.0; 1554.0)	600.5 (235.0; 1650.0)	643.0 (235.0; 1650.0)
^a Based on N=117 for placebo, N=115 for guselkumab 400 mg q4w → 100 mg SC q8w, N=114 for guselkumab 400 mg → 200 mg SC q4w, and N=346 for total. CDAI =Crohn's Disease Activity Index; CRP =C-reactive protein; GI =gastrointestinal; IQR =interquartile range; SC =subcutaneous; SD =standard deviation. SES-CD =Simple Endoscopic Score for Crohn's Disease.				


• Among all participants receiving oral CS (prednisone or budesonide) at baseline, greater proportions of guselkumab-treated participants vs placebo were: CS-free at Week 48, CS-free for ≥90 days prior to Week 48

Figure 2. Participants not receiving CS at Week 48 among those receiving CS at baseline

$\Delta = 62.9 (42.3, 83.4)$ $\Delta = 41.7 (18.4, 65.1)$		$\Delta = 62.9 (42.3, 83.4)$ $\Delta = 38.8 (15.6, 61.9)$		
--	--	---	--	--


Table 2. Baseline Crohn's disease medication history and concomitant medications





• At Week 48, greater proportions of guselkumab-treated participants vs placebo achieved: Clinical remission, CS-free clinical remission, 90-day CS-free clinical remission • 99.3% (144/145) of guselkumab-treated participants in clinical remission at Week 48 were CS-free





• At Week 48, greater proportions of guselkumab-treated participants vs placebo achieved: endoscopic response, 90-day CS-free endoscopic response


• 98.2% (108/110) of guselkumab-treated participants in endoscopic response at week 48 were CS-free for ≥90 days

Figure 4. Endoscopic response at Week 48

	Endoscopic response	90-day CS-free endoscopic response	90-day CS-free endoscopic response among participants receiving CS at baseline	
	Δ 44.6 (34.1, 55.0)	Δ 42.9 (32.5, 53.3)	Δ 42.8 (23.3, 62.4)	
100 -	Δ 37.5 (27.3, 47.7)	Δ 37.5 (27.3, 47.7)	Δ 41.5 (20.3, 62.7)	

History of previous biologic use, but no documented failure, n (%)	8 (6.8%)	7 (6.1%)	10 (8.7%)	25 (7.2%)
History of inadequate response/ intolerance^a to biologic therapy, n (%)	53 (45.3%)	55 (47.8%)	53 (46.1%)	161 (46.4%)
At least one anti-TNF ^b	50 (94.3%)	51 (92.7%)	52 (98.1%)	153 (95.0%)
Two or more anti-TNFs ^b	11 (20.8%)	12 (21.8%)	13 (24.5%)	36 (22.4%)
Vedolizumab	8 (15.1%)	13 (23.6%)	6 (11.3%)	27 (16.8%)
Concomitant Medications				
Participants with ≥1 Crohn's disease medication at baseline, n (%)	79 (67.5%)	74 (64.3%)	84 (73.0%)	237 (68.3%)
6-MP/AZA	33 (27.4%)	28 (24.3%)	36 (31.3%)	96 (27.7%)
Methotrexate	1 (0.9%)	1 (0.9%)	1 (0.9%)	3 (0.9%)
Oral aminosalicylates	50 (42.7%)	47 (40.9%)	44 (38.3%)	141 (40.6%)
Oral corticosteroid use	33 (28.2%)	32 (27.8%)	38 (33.0%)	103 (29.7%)
Corticosteroid use (excluding budesonide)	18 (15.4%)	15 (13.0%)	28 (24.3%)	61 (17.6%)
Median (IQR) daily prednisone- equivalent dose (excluding budesonide), ° mg	20 (10.0; 20.0)	20 (10.0; 25.0)	15.0 (10.0; 25.0)	_
Budesonide	15 (12.8%)	17 (14.8%)	10 (8.7%)	42 (12.1%)


No participants were receiving beclomethasone at baseline. ^aPrimary nonresponse, secondary nonresponse, or intolerance. ^bAmong participants with a history of inadequate response/intolerance to biologic therapy. ^cMedians and IQRs are based on the subset of participants receiving CS other than budesonide and beclomethasone dipropionate at baseline. 6-MP=6-mercaptopurine; AZA=azathioprine; IQR=interguartile range; SC=subcutaneous; TNF=tumor necrosis factor.



• At Week 48, greater proportions of guselkumab-treated participants vs placebo achieved: endoscopic remission, 90-day CS-free endoscopic remission • 97.5% (77/79) of guselkumab-treated participants in endoscopic remission at week 48 were CS-free for ≥90 days

Figure 5. Endoscopic remission at Week 48

Pro of



Δ = adjusted treatment difference. All participants in all treatment groups who met the rescue criteria were considered not to have met efficacy endpoints after Week 16. Participants who had a CD-related surgery (with the exception of minor procedures such as drainage of a superficial abscess or seton placement, etc.), a prohibited change in CD medication, met rescue criteria at Week 16 or discontinued study intervention for any reason (other than COVID-19 related reasons [excluding COVID-19 related reasons [excluding COVID-19 related reasons] or regional crisis] were considered not to have met the endpoint at the designated timepoint. COVID-19 infection) or regional crisis had their observed data used, if available. After accounting for the aforementioned data handling rules, participants who were missing data pertaining to an endpoint at a designated timepoint were considered not to have achieved the endpoint. The adjusted treatment difference(s), confidence interval(s), and p-value(s) were based on the common risk difference by use of Mantel-Haenszel stratum weights and the Sato variance estimator. The stratification factors are baseline (yes or no). CS-free outcomes are not multiplicity controlled. CI=confidence interval; **CS**=corticosteroid-free; **GUS**=guselkumab; **SC**=subcutaneous.

PRESENTED BY: A. Hart at the 20th Congress of European Crohn's and Colitis Organization (ECCO), February 19–22, 2025, Berlin, Germany. ACKNOWLEDGMENTS: Medical writing support was provided by Kristin Ruley Sharples, PhD of Johnson & Johnson Wers Squibb, and Janssen Research & Development, LLC., and has received research grants from Takeda and Johnson & Johnson. AH: reports serving as a lecturer and/or on an advisory board for Bristol Myers Squibb, Celltrion, Falk, AbbVie, Johnson, Takeda, Pfizer, Galapagos, MSD, and GSK. TH: reports grant support from Mitsubishi Tanabe Pharmaceutical Co. Ltd., Vipron Kayaku Co. Ltd., Vipron Kaya Pharmaceutical Co. Ltd., Boston Scientific Corporation, and Kissei Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Pfizer Inc., Eli Lilly, Gilead Sciences, Bristol Myers Squibb; and lecture fees from Mitsubishi Tanabe Pharma Corporation, AbbVie GK, EA Pharma Co. Ltd., Vorin Pharmaceutical K.K., Pfizer Inc., Eli Lilly, Gilead Sciences, Bristol Myers Squibb; and lecture fees from Mitsubishi Tanabe Pharmaceutical Co. Ltd., Pfizer Inc., Eli Lilly, Gilead Sciences, Bristol Myers Squibb; and lecture fees from Mitsubishi Tanabe Pharma Co. Ltd., Pfizer Inc., Eli Lilly, Gilead Sciences, Bristol Myers Squibb; and lecture fees from Mitsubishi Tanabe Pharma Co. Ltd., Pfizer Inc., Eli Lilly, Gilead Sciences, Bristol Myers Squibb; and lecture fees from Mitsubishi Tanabe Pharma Co. Ltd., Pfizer Inc., Eli Lilly, Gilead Sciences, Bristol Myers Squibb; and lecture fees from Mitsubishi Tanabe Pharma Co. Ltd., Pfizer Inc., Eli Lilly, Gilead Sciences, Bristol Myers Squibb; and lecture fees from Mitsubishi Tanabe Pharma Co. Ltd., Pfizer Inc., Eli Lilly, Gilead Sciences, Bristol Myers Squibb; and lecture fees from Mitsubishi Tanabe Pharma Co. Ltd., Pfizer Inc., Eli Lilly, Gilead Sciences, Bristol Myers Squibb; and lecture fees from Mitsubishi Tanabe Pharma Co. Ltd., Pfizer Inc., Eli Lilly, Gilead Sciences, Bristol Myers Squibb; and lecture fees from Mitsubishi Tanabe Pharma Co. Ltd., Pfizer Inc., Eli Lilly, Gilead Sciences, Bristol Myers Squibb; and lecture fees from Mitsubishi Tanabe Pharma Co. Ltd., Pfizer Inc., Eli Lilly, Gilead Sciences, Bristol Myers Squibb; and lecture fees from Mitsubishi Tanabe Pharma Co. Ltd., Pfizer Inc., Eli Lilly, Gilead Sciences, Bristol Myers Squibb; and lecture fees from Mitsubishi Tanabe Pharma Co. Ltd., Pfizer Inc., Eli Lilly, Gilead Sciences, Bristol Myers Squibb; and Iccure fees from Mitsubishi Tanabe Pharma Co. Ltd., Pfizer Inc., Eli Lilly, Gilead Sciences, Bristol Myers Squibb; and Iccure fees from Mitsubishi Tanabe Pharma Co. Ltd., Pfizer Inc., Eli Lilly, Gilead Sciences, Bristol Myers and Kissei Pharmaceutical Co. Ltd. MO, ZY, EM, and NAT: are employees of Johnson & Johnson & Johnson & Interest and/or on an advisory board for AbbVie, AbbiVax, Alimentiv (formerly Robarts), Amgen, AnaptysBio, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, and Kissei Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, and Kissei Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, and Kissei Pharmaceuticals (formerly Robarts), Amgen, AnaptysBio, Arena Pharmaceuticals, AstraZeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, and Kissei Pharmaceuticals (formerly Robarts), Amgen, and Fresenius-Kabi. Resenius-Kabi. Resenius-Kabi Celltrion, Cosmos Pharmaceuticals, Eisai, Elan, Eli Lilly, Ferring, Galapagos, Fresenius Kabi, Genentech, Oppilan Pharma, Organon, Pandion Pharmaceuticals, Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity, Prometheus Biosciences, Protagonist Therapeutics, Therapeutics, Therapeutics, Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity, Prometheus Biosciences, Protagonist Therapeutics, Therapeutics, Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity, Prometheus Biosciences, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity, Therapeutics, Therapeutics, Therapeutics, Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity, Prometheus Biosciences, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity, Prometheus Biosciences, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity, Prometheus Biosciences, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity, Prometheus Biosciences, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity, Prometheus Biosciences, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity, Prometheus Biosciences, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity, Prometheus Biosciences, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity, Prometheus Biosciences, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity, Prometheus Biosciences, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Sublimity, Prometheus Biosciences, Protagonist Therapeutics, Roche, Sandoz, Satisfai Health, Shire, Satisfai H Pharmaceuticals, Bristol Myers Squibb, Celgene, Eli Lilly, Ferring, Fresenius Kabi, Gilead Sciences, GSK, JAMP Bio, Janssen, Merck, Mylan, Novartis, Oppilan Pharma, Organon, Pandion Pharma, Pfizer, Progenity, Protagonist Therapeutics, Roche, Sandoz, Shire, Sublimity Therapeutics, Takeda Pharmaceutical support from Adiso Therapeutics, personal fees from Angen, personal fees from Angen, personal fees and non-financial support from Adiso Therapeutics, personal fees from Adiso Therapeutics, personal fees and non-financial support from AstraZeneca, personal fees from Biolojic Design, personal fees from Enveda Biosciences, personal fees from Enveda Genentech, personal fees from Ges from Ges from Ges from Kaleido, personal fees from Kaleido, personal fees from Johnson, personal fees from Kaleido, personal fees from Johnson, personal fees from Kaleido, personal fees from GossamerBio, personal fees from Kaleido, personal fees from Kaleido, personal fees and non-financial support from Johnson, personal fees from Kaleido, personal fees and non-financial support from Kaleido, personal fees from Microba, personal fees from Mobius Care, personal fees from Mexus Therapeutics, personal fees from Morphic Therapeutics, personal fees from Morphic Therapeutics, personal fees from Mexus Therapeutics, personal fees from Morphic Therapeutics, personal fees from Mexus Therapeutics, personal fees from Mexis Therapeutics, support from Prometheus Biosciences, personal fees from Resonal fe personal fees from Theravance Biopharma, personal fees from TLL Pharmaceutical, personal fees from TR1X, personal fees from Union Therapeutics, stock, and stock options, personal fees from TR1X, personal fees from Union Therapeutics, stock, and stock options, personal fees from TR1X, personal fees from TR1X, personal fees from Union Therapeutics, stock, and stock options, personal fees from TR1X, personal fees from Union Therapeutics, stock, and stock options, personal fees from TR1X, personal fees from TR1X, personal fees from TR1X, personal fees from Union Therapeutics, stock, and stock options, personal fees from Union Therapeutics, stock, and stock options, personal fees from TR1X, personal fees from